AUROPHARMA Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > auropharma

Technical Analysis

Technical Strength: 7.5 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 56.5. According to RSI analysis, auropharma is strong. 7.0 AUROPHARMA RSI Chart
MACD (?) MACD: 7.19 and Signal Line: 3.41. According to MACD analysis, auropharma is technically strong. 8.0 AUROPHARMA MACD Chart
Simple Moving Average (?) According to simple moving average analysis, auropharma is in a uptrend. Support level is at 730. 9.0 AUROPHARMA Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, auropharma is in a strong uptrend. Major support levels are 739.8235, 729.0167, 701.512. 10.0 AUROPHARMA Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.75. According to bollinger bands, auropharma is technically strong. 7.0 AUROPHARMA Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 733.598 and 720.5. Resistance level is 776.0. 6.5 AUROPHARMA Fibonacci Retracement Chart
Average True Range (?) ATR: 19.7 NA AUROPHARMA Average True Range Chart
Average Directional Index (?) ADX is 15.8 which means AUROPHARMA is in a trading range and there is no trend. NA AUROPHARMA Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
October 19, 2017
Open Price 757.2
High Price 760.9
Low Price 750.05
Close Price 754.05
Absolute Change -1.95
Percentage Change -0.258%
Weekly Change 0.944%
Monthly Change 1.14%
Yearly Change -6.85%
52-week high 840.4
52-week low 503.05
Corporate Actions
ExDate Purpose
June 08, 2017 INT DIV RS 1.25 PER SHARE
June 09, 2016 INT DIV-RE 0.70 PER SHARE
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)1.16
Confidence in Beta2.47%
Market Capital Rs. 44037.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 20.9771875
TTM Price-to-Earnings (P/E) Ratio 35.9
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 19 October 2017: Deliverable Quantity:8.16e+04 NA AUROPHARMA Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 19 October 2017: Daily Volatility:0.3343 NA AUROPHARMA Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 19 October 2017: PCR_OI:0.744 PCR:0.362 NA AUROPHARMA PCR Chart
Option Pain (?) 19 October 2017: Max Pain:760.0 NA AUROPHARMA Option Pain Chart
Premium (?) 19 October 2017 Premium: 1.5 Futures OI:16317600.0 NA AUROPHARMA Premium Chart
Option_MAX_OI (?) 19 October 2017: Price:754.05 Put with maximum OI:740.0 Call with maximum OI:780.0 NA AUROPHARMA Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
October 26, 2017 755.55 16317600.0 837.0 942.0 754.05
November 30, 2017 758.75 610400.0 72.0 89.0 754.05


October 17, 2017 Press Release Aurobindo Pharma Limited has informed the Exchange regarding a press release dated October 17, 2017, titled "Aurobindo Pharma receives USFDA Approval for Esomeprazole Magnesium DR Capsules OTC".
September 21, 2017 Analysts/Institutional Investor Meet/Con. Call Updates Aurobindo Pharma Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
See all Announcements

Board Meetings

Date Meeting Date Purpose
July 27, 2017 August 09, 2017 Results To consider and approve, inter alia, the Un-audited Financial Results of the Company for the first quarter ended June 30, 2017.
May 18, 2017 May 29, 2017 Results/Dividend to consider and approve, inter alia, the Audited Financial Results of the Company for the year ended March 31, 2017 and also to consider dividend, if any, for the financial year 2016-17.
See all Board Meetings

AUROPHARMA is part of...

Index Weightage

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 738.2 Rs. 744.1 Rs. 749.1 Rs. 755 Rs. 760 Rs. 765.9 Rs. 770.8